Global Intravenous Immunoglobulins Market to Grow at a CAGR of 7.6% by 2021 - Key Vendors Are CSL Behring, Grifols, Octapharma & Shire - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Intravenous Immunoglobulins Market 2017-2021" report to their offering.

The global intravenous immunoglobulins market to grow at a CAGR of 7.62% during the period 2017-2021.

The report, Global Intravenous Immunoglobulins Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is monetary support to plasma donors. The intravenous immunoglobulin market is growing at steady rate, where the number of plasma donors affects the overall supply chain. Therefore, to maintain and meet the demands of plasma-derived therapeutics, a plasma donor receives monetary compensation.

According to the report, one driver in the market is growing number of fractionating units. Fractionation is a crucial step in the manufacture of immunoglobulins. This step involves separation of immunoglobulins and other blood protein from plasma. The capacity of fractionating units is increasing. Data estimates suggest that during 2013-2016, the capacity increased by 39.5%. This increased capacity is primarily due to the installment of new fractionating units or expansion of existing fractionating units.

Key vendors

  • CSL Behring
  • Grifols
  • Octapharma
  • Shire

Other prominent vendors

  • ADMA Biologics
  • Bayer
  • Bharat Serum and Vaccines
  • Biotest AG
  • China Biologic Products
  • Hualan Biological Engineering
  • Kedrion Biopharma
  • LFB Group
  • Sanquin

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of diseases treated using intravenous immunoglobulins

PART 06: Market landscape

PART 07: Pipeline landscape

PART 08: Market segmentation by Therapy area

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/jvzz96/global

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs